analysis software local app v 2.2 (Illumina Inc)
Illumina Inc is a verified supplier 
90
Structured Review
Illumina Inc
analysis software local app v 2.2
Analysis Software Local App V 2.2, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/analysis+software+local+app+v+2%2E2/analysis+software+local+app+v+2+2/pm40250790-132-14-14
Average 90 stars, based on 1 article reviews
Analysis Software Local App V 2.2, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/analysis+software+local+app+v+2%2E2/analysis+software+local+app+v+2+2/pm40250790-132-14-14
Average 90 stars, based on 1 article reviews
analysis software local app v 2.2 - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: Multiplex characterization of circulating tumor cells from ductal carcinoma in situ patients suggests early tumor dissemination. Article Snippet: While ducal carcinoma in situ (DCIS) is considered to be pre-invasive, some patients will develop metastatic disease after a long disease-free interval.. The prevailing dogma posits that invasive local recurrence is the source of subsequent metastasis, and thus the goal of DCIS therapy is the prevention of local recurrence.. Recently, this paradigm has been called into question by the observation that some women develop metastatic disease in the absence of local recurrence or even following bilateral mastectomies, suggesting early cancer dissemination in some patients. |